Vaccine for falciparum malaria
The invention provides compositions and methods for preventing or reducing the severity of malaria.
1. A vaccine for reducing the severity of malaria or immunizing against malaria comprising a composition, wherein said composition comprises a purified PF3D7 polypeptide antigen comprising the amino acid sequence of SEQ ID NO: 47, or a fragment thereof, said fragment thereof comprising the amino acid sequence of DYTEFLAACLDHSIFQQDVICRNAFNVFDLDGDGVITKDELFKILSFSAVQVSFSKEIIENLIKEVDSNN DGFIDYDEFYKMMTGVKE (SEQ ID NO:77), and further comprising a purified anti-PF3D7 antibody or antigen binding fragment thereof and an adjuvant.
2. The vaccine of claim 1 , wherein said composition comprises a purified polypeptide comprising the amino acid sequence of DYTEFLAACLDHSIFQQDVICRNAFNVFDLDGDGVITKDELFKILSFSAVQVSFSKEIIENLIKEVDSNN DGFIDYDEFYKMMTGVKE (SEQ ID NO:77).
3. A vaccine for reducing the severity of malaria or immunizing against malaria comprising a composition, wherein said composition comprises a purified PF3D7 polypeptide antigen comprising the amino acid sequence of (SEQ ID NO: 47) or a fragment thereof, said fragment thereof comprising the amino acid sequence of DYTEFLAACLDHSIFQQDVICRNAFNVFDLDGDGVITKDELFKILSFSAVQVSFSKEIIENLIKEVDSNNDGFIDYD EFYKMMTGVKE (SEQ ID NO: 77), wherein said composition further comprises an adjuvant and a purified polypeptide comprising the amino acid sequence of SERA5 (SEQ ID NO: 70, 72), PfSUB1 (SEQ ID NO: 74), PfSEP1 (SEQ ID NO: 2), PfSEP1 (SEQ ID NO: 3), PfGARP (SEQ ID NO: 26), PfGARP (SEQ ID NO: 27), or PfPKG (SEQ ID NO: 76).
4. The vaccine of claim 1 , wherein said composition comprises a purified polypeptide that elicits an antibody immune response against PF3D7.
5. The vaccine of claim 4 , wherein said antibody immune response produces antibodies that bind to an antigen comprising a polypeptide having at least 70% identity with an amino acid sequence of SEQ ID NO: 47 or a fragment thereof.
6. A vaccine for reducing the severity of malaria or immunizing against malaria comprising a composition, wherein said composition comprises a purified PF3D7 polypeptide antigen comprising the amino acid sequence of (SEQ ID NO: 47) or a fragment thereof, said fragment thereof comprising the amino acid sequence of DYTEFLAACLDHSIFQQDVICRNAFNVFDLDGDGVITKDELFKILSFSAVQVSFSKEIIENLIKEVDSNNDGFIDYD EFYKMMTGVKE (SEQ ID NO: 77), wherein said composition further comprises an adjuvant and a purified polypeptide comprising an amino acid sequence selected from the group consisting of SEQ ID NO: 10, 14, 18, 22, 30, 34, 38, 42, 46, 66 and 72.
7. A vaccine for reducing the severity of malaria or immunizing against malaria comprising a composition, wherein said composition comprises a purified PF3D7 polypeptide antigen comprising the amino acid sequence of (SEQ ID NO: 47) or a fragment thereof, said fragment thereof comprising the amino acid sequence of DYTEFLAACLDHSIFQQDVICRNAFNVFDLDGDGVITKDELFKILSFSAVQVSFSKEIIENLIKEVDSNNDGFIDYD EFYKMMTGVKE (SEQ ID NO: 77), wherein said composition further an adjuvant and comprises a purified polypeptide comprising an amino acid sequence selected from the group consisting of SEQ ID NO: 8, 11, 15, 19, 22, 31, 35, 39, 43, 67, 70, 74, and 76 or fragments thereof.
8. A vaccine for reducing the severity of malaria or immunizing against malaria comprising a composition, wherein said composition comprises a purified PF3D7 polypeptide antigen comprising the amino acid sequence of (SEQ ID NO: 47) or a fragment thereof, said fragment thereof comprising the amino acid sequence of DYTEFLAACLDHSIFQQDVICRNAFNVFDLDGDGVITKDELFKILSFSAVQVSFSKEIIENLIKEVDSNNDGFIDYD EFYKMMTGVKE (SEQ ID NO: 77), wherein said composition further comprises an adjuvant and a purified polypeptide consisting of an amino acid sequence selected from the group consisting of SEQ ID NO: 6, 7, 10, 11, 14, 15, 18, 19, 22, 23, 30, 31, 34, 35, 38, 39, 42, 43, 46, 66, 67, 70, 72, 74, and 76 or an immunogenic fragment thereof.
9. A vaccine for reducing the severity of malaria or immunizing against malaria comprising a composition, wherein said composition comprises a purified PF3D7 polypeptide antigen comprising the amino acid sequence of (SEQ ID NO: 47) or a fragment thereof, said fragment thereof comprising the amino acid sequence of DYTEFLAACLDHSIFQQDVICRNAFNVFDLDGDGVITKDELFKILSFSAVQVSFSKEIIENLIKEVDSNNDGFIDYD EFYKMMTGVKE (SEQ ID NO: 77), wherein said composition further comprises an adjuvant and a purified polypeptide comprising an amino acid sequence of 6, 7, 10, 11, 14, 15, 18, 19, 22, 23, 30, 31, 34, 35, 38, 39, 42, 43, 46, 66, 67, 70, 72, 74, and/or 76.
10. The vaccine of claim 1 , wherein said antigen comprises a polypeptide encoded by a polynucleotide having at least 70% identity with the nucleic acid sequence of SEQ ID NO: 48.
11. The vaccine of claim 10 , wherein said polypeptide is encoded by a polynucleotide having the nucleic acid sequence of SEQ ID NO: 48.
12. A method for reducing the severity of malaria or immunizing against malaria comprising a composition, wherein said composition comprises a purified PF3D7 polypeptide antigen comprising the amino acid sequence of (SEQ ID NO: 47) or a fragment thereof, said fragment thereof comprising the amino acid sequence of DYTEFLAACLDHSIFQQDVICRNAFNVFDLDGDGVITKDELFKILSFSAVQVSFSKEIIENLIKEVDSNN DGFIDYDEFYKMMTGVKE (SEQ ID NO:77), and further comprising a purified anti-PF3D7 antibody or antigen binding fragment thereof and an adjuvant.